Shukra Pharmaceuticals Ltd

₹ 28.0 -3.38%

25 May - close price

About

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing^[1]

Key Points

Business Overview:^[1]^[2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies

Website BSE

Market Cap ₹ 1,227 Cr.
Current Price ₹ 28.0
High / Low ₹ 65.3 / 12.8
Stock P/E 55.6
Book Value ₹ 2.05
Dividend Yield 0.04 %
ROCE 36.9 %
ROE 28.9 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company is expected to give good quarter
Company has delivered good profit growth of 175% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 28.2%

Cons

Stock is trading at 13.7 times its book value
Debtor days have increased from 122 to 148 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	46.25	20.16	24.64	18.89	10.88	3.18	5.56	10.58	13.27	5.39	5.88	39.13	6.30
	42.60	19.82	19.55	9.34	6.45	2.38	4.90	6.65	5.96	4.07	6.29	12.00	5.61
Operating Profit	3.65	0.34	5.09	9.55	4.43	0.80	0.66	3.93	7.31	1.32	-0.41	27.13	0.69
OPM %	7.89%	1.69%	20.66%	50.56%	40.72%	25.16%	11.87%	37.15%	55.09%	24.49%	-6.97%	69.33%	10.95%
	0.89	0.63	0.24	0.56	1.38	0.72	1.02	1.01	1.47	1.11	1.71	0.82	0.95
Interest	0.07	0.08	0.06	0.07	0.07	0.06	0.11	0.15	0.27	0.27	0.29	0.28	0.26
Depreciation	0.51	0.46	0.56	0.51	0.52	0.67	0.70	0.70	0.94	0.79	0.81	0.84	1.01
Profit before tax	3.96	0.43	4.71	9.53	5.22	0.79	0.87	4.09	7.57	1.37	0.20	26.83	0.37
Tax %	-0.25%	2.33%	-0.21%	1.05%	23.75%	40.51%	39.08%	22.74%	28.80%	25.55%	-1,090.00%	24.08%	567.57%
	3.98	0.42	4.71	9.42	3.99	0.49	0.54	3.16	5.39	1.03	2.38	20.36	-1.73
EPS in Rs	0.09	0.01	0.11	0.22	0.09	0.01	0.01	0.07	0.12	0.02	0.05	0.46	-0.04
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	3	5	5	5	6	12	11	20	59	75	33	57
	3	4	4	4	4	10	10	18	53	55	20	28
Operating Profit	-0	1	1	2	2	2	1	3	5	19	13	29
OPM %	-10%	24%	28%	30%	29%	13%	13%	14%	9%	26%	39%	51%
	1	-0	0	0	0	0	0	0	1	3	4	5
Interest	0	0	0	0	0	0	0	0	0	0	1	1
Depreciation	1	0	0	1	1	1	1	2	2	2	3	3
Profit before tax	0	0	1	1	1	0	0	1	4	20	13	29
Tax %	52%	66%	52%	45%	37%	82%	-90%	26%	1%	7%	28%	23%
	0	0	0	1	0	0	0	1	4	19	10	22
EPS in Rs	0.00	0.00	0.01	0.01	0.01	0.00	0.00	0.02	0.10	0.42	0.22	0.50
Dividend Payout %	0%	0%	16%	15%	17%	0%	0%	10%	4%	6%	5%	0%

Compounded Sales Growth
10 Years:	28%
5 Years:	38%
3 Years:	-1%
TTM:	74%

Compounded Profit Growth
10 Years:	53%
5 Years:	175%
3 Years:	71%
TTM:	130%

Stock Price CAGR
10 Years:	55%
5 Years:	138%
3 Years:	121%
1 Year:	111%

Return on Equity
10 Years:	20%
5 Years:	26%
3 Years:	28%
Last Year:	29%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2	2	2	2	2	2	2	2	4	11	44	44
Reserves	12	13	13	13	14	14	14	15	21	47	19	46
	1	0	0	4	6	8	10	3	5	3	4	5
	3	3	4	6	7	10	10	15	45	17	20	23
Total Liabilities	18	17	19	24	28	34	36	35	75	78	87	117
	10	10	10	14	16	17	18	18	20	20	19	22
CWIP	2	2	2	2	2	2	2	2	2	2	2	12
Investments	0	0	0	0	0	0	0	0	0	0	0	0
	7	6	7	8	11	14	16	16	53	56	65	84
Total Assets	18	17	19	24	28	34	36	35	75	78	87	117

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-2	3	-0	1	0	1	1	8	3	-5	8	3
	1	-0	-1	-5	-2	-3	-2	-2	-4	-1	-1	-14
	1	-1	0	3	2	2	2	-7	5	12	-5	5
Net Cash Flow	0	1	-1	-0	0	-0	0	-0	4	6	2	-6
Free Cash Flow	-1	2	-1	-4	-2	-2	-1	6	-1	-7	5	-13
CFO/OP	812%	237%	7%	63%	25%	81%	38%	292%	64%	-24%	92%	17%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	73	71	175	200	345	245	318	132	187	120	98	148
Inventory Days	554	92	112	53	100	169	221	139	25	19	447	320
Days Payable	291	108	400	734	1,161	786	702	303	271	59	414	232
Cash Conversion Cycle	335	54	-112	-480	-717	-372	-163	-32	-58	80	131	236
Working Capital Days	758	258	344	379	440	226	278	57	41	157	404	352
ROCE %	-1%	6%	7%	6%	4%	0%	1%	6%	19%	44%	22%	37%

Insights

In beta

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Debtors Turnover Ratio
Ratio

x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
xx	xx	xx	xxx	xxx	x	xxx
						xx

Please log in to see hidden values.

Number of Permanent Employees
Number

Manufacturing Facility Land Size
Acres

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	50.90%	50.90%	50.95%	50.95%	50.95%	50.95%	50.95%	50.95%	50.95%	50.95%	50.95%	50.95%
	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%
	48.99%	48.99%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.92%
No. of Shareholders	9,582	9,747	10,963	12,974	14,989	16,321	17,844	18,231	20,337	21,441	25,649	27,173

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	49.17%	49.17%	49.17%	49.17%	49.17%	49.17%	50.90%	50.95%	50.95%	50.95%
	0.80%	0.80%	0.80%	0.80%	0.80%	0.80%	0.11%	0.11%	0.11%	0.11%
	50.04%	50.04%	50.04%	50.04%	50.04%	50.04%	48.99%	48.93%	48.93%	48.92%
No. of Shareholders	9,706	9,577	9,468	9,455	9,345	9,239	9,531	12,974	18,231	27,173

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports